Tenax shares Phase 3 LEVEL trial data at ESC Congress 2026

August 29, 2026 8:21 AM

Tenax Therapeutics (Nasdaq: TENX) presented additional results from its Phase 3 LEVEL clinical trial of TNX-103 (oral levosimendan) at the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found